FDA Approves First Treatment for Cerebral Folate Transport Deficiency
The U.S. Food and Drug Administration (FDA) has approved an expanded use of Wellcovorin (leucovorin calcium) tablets to treat patients with cerebral folate deficiency caused by variants in the folate receptor 1 gene (CFD-FOLR1). The approval applies to both adult and pediatric patients and represents the first FDA-approved treatment for this rare genetic condition.
Cerebral folate deficiency is a neurological disorder in which the body cannot properly transport folate, a vitamin essential for brain development, into the central nervous system. Patients with CFD-FOLR1 often experience severe developmental delays, seizures, movement disorders, and other neurological complications.
According to FDA Commissioner Marty Makary, M.D., M.P.H., the approval reflects the agency’s efforts to accelerate treatments for patients with serious conditions that currently lack effective therapies.
Evidence from Published Literature and Real-World Data
Unlike many drug approvals that rely primarily on large randomized clinical trials, the FDA based this decision largely on a systematic review of published scientific literature, including case reports containing patient-level clinical data and mechanistic studies explaining the drug’s biological effects.
Regulators also evaluated real-world evidence demonstrating clinical improvement in patients compared with the natural course of the disease. Acting Director of the FDA’s Center for Drug Evaluation and Research Tracy Beth Hoeg, M.D., Ph.D., noted that the approval illustrates how observational evidence can support regulatory decisions in rare diseases where traditional clinical trials may be difficult to conduct.
Regulatory Collaboration
The FDA worked with GSK, the holder of the New Drug Application (NDA) for Wellcovorin, to update the drug’s labeling with the information needed for safe and effective use in patients with CFD-FOLR1.
This type of labeling update allows an existing therapy to be formally recognized as an FDA-approved treatment for a specific rare disease indication.
Safety Information
Leucovorin is generally well understood, but potential side effects include itching (pruritus), rash and hives, breathing difficulty (dyspnea), chills or shivering (rigors), and impaired temperature regulation. In rare cases, anaphylaxis, a severe allergic reaction, may occur requiring immediate medical treatment.
Significance for Rare Disease Patients
The approval provides the first FDA-recognized therapy for individuals with CFD-FOLR1 and highlights the agency’s increasing use of flexible evidentiary approaches when evaluating treatments for ultra-rare conditions. By incorporating literature reviews, mechanistic data, and real-world clinical evidence, regulators were able to support approval for a therapy addressing a serious unmet medical need.
For more information, click the download box in the right column of this post to review the supplemental approval document and click here to see the FDA announcement.
Download the GSK Supplemental Approval Letter
Pimicotinib (Pimjetmi) for Tenosynovial Giant Cell Tumor
On November 10, 2026, the Food and Drug Administration approved pimicotinib (Pimjetmi, EMD Serono, Inc.), a kinase inhibitor, for adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection may cause worsening functional limitation or...
Eugia Vancomycin Recall: Glass Particle Contamination
FDA announces voluntary recall of a single lot of vancomycin hydrochloride for injection because of potentially dangerous particulate contamination.Eugia US LLC, formerly Auro Medics Pharma LLC, has initiated a voluntary nationwide recall of one lot of Vancomycin...
FDA Requires New GLP-1 Drug Warning for Vision Loss Risk
Agency cites potential increased risk of rare optic nerve condition following review of clinical trials and postmarket safety dataThe U.S. Food and Drug Administration (FDA) is requiring manufacturers of all glucagon-like peptide-1 receptor agonist (GLP-1 RA)...
When Political Priorities and FDA Science Collide
HHS proposes expanding access to six unapproved peptides despite objections from FDA scientists. This raises questions about regulatory oversight, patient safety, and the distinction between enforcement discretion and drug approval.The Trump administration is moving...
What to Know about FDA’s Revised Peptide Guidance
What Manufacturers Need to Know Seventeen revised draft product-specific guidance documents reflect FDA's evolving scientific and regulatory approach to generic peptide drug development. On July 28, 2026, the U.S. Food and Drug Administration (FDA) published 17...
The Regulatory Dilemma of Experimental Peptides
As demand for experimental peptides grows, a fundamental question confronts federal regulators. Can access to unapproved drug products expand without compromising the standards intended to protect patients? The growing popularity of experimental peptides such as...